NZD/USD jumped after the RBNZ’s hawkish rate cut, but the pair now faces key resistance and may resume its broader downtrend amid rising US rate cut expectations.
Full FDA approval for one of its drugs, an excellent earnings report, and a deep pipeline support the bullish trend. Is there more room to the upside for Amgen?